Study #2016-0069
Phase II Study of Oral Azacitidine (CC-486) in Combination with Pembrolizumab (MK-3475) in Patients with Metastatic Melanoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Azacitidine, Pembrolizumab
Description
You are being asked to take part in this study because you have advanced melanoma. The goal of this clinical research study is to learn if oral azacitidine (CC-486) and pembrolizumab (MK-3475) can help to control melanoma. The safety of this drug combination will also be studied. This is an investigational study. Azacitidine is FDA approved and commercially available for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia. Pembrolizumab is FDA approved and commercially available for the treatment of melanoma. It is considered investigational to use this drug combination to treat melanoma. The study doctor will explain how the study drugs are designed to work. Up to 71 participants will be enrolled in this study. All will take part at MD Anderson.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
Study phase:
Phase II
Physician name:
Hussein Tawbi
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-463-0259
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.